TLCD2: A Potential Drug Target and Biomarker for Human Diseases

Target Name: TLCD2

NCBI ID: G727910

TLCD2

Other Name(s): TLCD2_HUMAN | TLC domain-containing protein 2 | TLC domain containing 2

TLCD2: A Potential Drug Target and Biomarker for Human Diseases

TLCD2 (TLCD2_HUMAN) is a protein that is expressed in various tissues of the human body. It is a member of the superfamily of leucine-rich repeat (LRR) proteins, which are characterized by the presence of a leucine-rich repeat in their amino acid sequence. TLCD2 is highly conserved between various species, and its sequence has been identified in many different organisms, including humans.

TLCD2 is involved in a variety of cellular processes that are important for normal development and maintenance of tissues. It is involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. TLCD2 is also involved in the regulation of cell signaling, which is the process by which cells communicate with each other to coordinate their activities.

TLCD2 is a potential drug target because of its involvement in cellular processes that are important for human health. For example, TLCD2 has been shown to be involved in the development and progression of many different diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In addition to its potential as a drug target, TLCD2 is also a potential biomarker for the diagnosis and monitoring of these diseases. For example, TLCD2 has been shown to be expressed in the brains of patients with Alzheimer's disease, which is a neurodegenerative disease that is characterized by the progressive loss of brain cells. This suggests that TLCD2 may be a useful biomarker for the diagnosis and monitoring of Alzheimer's disease.

TLCD2 is also a potential target for therapeutic intervention because of its involvement in the regulation of cellular processes that are important for human health. For example, TLCD2 has been shown to be involved in the regulation of cell signaling, which is the process by which cells communicate with each other to coordinate their activities. This suggests that TLCD2 may be a useful target for therapeutic intervention in a variety of diseases.

In conclusion, TLCD2 is a protein that is expressed in various tissues of the human body. It is a member of the superfamily of leucine-rich repeat (LRR) proteins, and it is involved in a variety of cellular processes that are important for normal development and maintenance of tissues. TLCD2 is a potential drug target and biomarker for the diagnosis and monitoring of many different diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. It is also a potential target for therapeutic intervention in these diseases.

Protein Name: TLC Domain Containing 2

Functions: Regulates the composition and fluidity of the plasma membrane (PubMed:30509349). Inhibits the incorporation of membrane-fluidizing phospholipids containing omega-3 long-chain polyunsaturated fatty acids (LCPUFA) and thereby promotes membrane rigidity (PubMed:30509349). Does not appear to have any effect on LCPUFA synthesis (PubMed:30509349)

The "TLCD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TLCD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets